Side-by-side comparison of AI visibility scores, market position, and capabilities
Telehealth platform with $872M 2024 revenue; GLP-1 weight loss, hair, and sexual health prescriptions shipped directly to 2M+ subscribers; went public via SPAC merger in 2021; compounded medications and same-day shipping differentiate from traditional telehealth.
Hims & Hers Health is a telehealth and wellness platform offering personalized treatment plans and prescription medications for conditions including hair loss, erectile dysfunction, weight management, skincare, and mental health. Founded in 2017 and headquartered in San Francisco, Hims & Hers went public via SPAC merger in January 2021 and has grown into a $1B+ revenue publicly traded health company. The platform connects patients with licensed providers asynchronously and ships prescription treatments directly to homes, eliminating the friction of in-person doctor visits for lifestyle health conditions.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.